Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NXC-201 |
Synonyms | |
Therapy Description |
NXC-201 is a chimeric antigen receptor (CAR)-T cell therapy targeting TNFRSF17 (BCMA), which potentially decreases tumor growth (PMID: 38768428). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NXC-201 | NXC201|NXC 201|HBI0101|HBI-0101|HBI 0101 | NXC-201 is a chimeric antigen receptor (CAR)-T cell therapy targeting TNFRSF17 (BCMA), which potentially decreases tumor growth (PMID: 38768428). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04720313 | Phase I | NXC-201 | NXC-201 (Formerly HBI0101) Multiple Myeloma | Recruiting | ISR | 0 |